ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
PORTLAND, Maine, March 18, 2026 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee.
Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcare and animal health markets and previously served on the Board of Directors of Elanco Animal Health, a leading animal health company. From 2014 to 2023, she held senior leadership roles at IDEXX Laboratories, including most recently serving as Chief Marketing Officer and Senior Vice President of International Operations, where she contributed to sustained double-digit growth across international markets. Prior to that, Ms. Turner spent nearly 30 years at Abbott Laboratories, where she held multiple leadership roles in global commercial operations. She currently serves on the Board of Veterinarians Without Borders.
Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell, commented, “Kathy brings deep experience across the global animal health industry, including her service on the Board of Elanco Animal Health and her leadership in scaling international businesses at IDEXX and Abbott. Her perspective will strengthen our Board as we pursue opportunities to extend the reach of First Defense
Ms. Turner said, “I am excited to join the Board of ImmuCell. Its hyperimmune colostrum technology and First Defense
The Company sincerely thanks Mr. Rosgen for his many valuable contributions during 8 years of dedicated service.
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal health biologics company serving the dairy and beef industries with practical, science-based solutions that improve the survivability, health, and long-term performance of dairy and beef calves. The Company’s primary product line, First Defense
| Contacts: | Olivier te Boekhorst, President and CEO Timothy C. Fiori, Chief Financial Officer ImmuCell Corporation |
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Shopify Stock Rally Isn't Done: Chart of the Week -- Barrons.com
By Doug Busch Shopify is no longer a pandemic-era growth story that simply failed to slow down. It is compounding at a pace few software platforms its size still manage. In the second quarter of 2026, sales on its platform rose 32%. That was the fifth straight quarter of growth exceeding 30%. Merchants are also using more of Shopify's own tools, from payments to Shop Pay, and new channels like AI shopping agents are starting to increase demand. The simple bull case is that the stock already commands a huge share of independent online commerce, and that position should become more valuable as more buying moves through its checkout. A rule of market mechanics is that the vast majority of an individual security's gain is driven by its underlying sector. Within technology, software has staged a robust recovery, joining semiconductors to power the broader sector higher. The iShares Expanded Tech-Software Sector ETF has maintained an upward trajectory since its mid-April lows, though the advance from $74 to $112 has been choppy as bulls repeatedly stepped in to defend when necessary. Breadth across large-cap software has expanded significantly, with 24 constituents surging over 20% over the past three months. During that same three-month window, Shopify generated outstanding relative strength, advancing 36%, more than doubling the IGV's 17% gain over the same period. Expect the stock's outperformance to persist as software momentum broadens. Let's examine the daily and monthly charts to outline the technical drivers behind this thesis. Looking at the daily chart, the ratio chart against the IGV shows persistent outperformance extending back to mid-May. The stock is riding an eight-session winning streak, during which price action cleared a double-bottom-with-handle pivot at $151.39. Within this broader base, the stock recorded a bullish golden cross in late August and successfully filled its Sept. 10 price gap, tracing back to its Aug. 4 session, the day before a powerful earnings reaction sent the stock surging 17% hi
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
Talos Energy director Barbara J. Faulkenberry files initial beneficial ownership statement
Talos Energy director Barbara J. Faulkenberry filed an initial Form 3 statement dated Oct. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talos Energy Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418248), on October 08, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
